Epoch Investment Partners Inc. Takes Position in Cambrex Co. (CBM)
Epoch Investment Partners Inc. acquired a new stake in Cambrex Co. (NYSE:CBM) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 133,634 shares of the biotechnology company’s stock, valued at approximately $5,046,000. Epoch Investment Partners Inc. owned 0.40% of Cambrex as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Enlightenment Research LLC acquired a new position in Cambrex in the 4th quarter valued at approximately $30,000. Private Capital Group LLC increased its stake in shares of Cambrex by 25.9% during the 4th quarter. Private Capital Group LLC now owns 1,503 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 309 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new position in shares of Cambrex during the 4th quarter worth $79,000. Bruderman Asset Management LLC acquired a new position in shares of Cambrex during the 4th quarter worth $125,000. Finally, BlueMountain Capital Management LLC acquired a new position in shares of Cambrex during the 3rd quarter worth $144,000.
Shares of CBM opened at $39.50 on Friday. Cambrex Co. has a 12 month low of $33.80 and a 12 month high of $69.43. The firm has a market cap of $1.33 billion, a PE ratio of 14.26, a price-to-earnings-growth ratio of 3.47 and a beta of 2.42. The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46.
Several research analysts have recently commented on CBM shares. Craig Hallum dropped their price target on shares of Cambrex from $71.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, February 14th. ValuEngine lowered shares of Cambrex from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 31st. Jefferies Financial Group lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $43.00 price target on the stock. in a research note on Friday, February 22nd. Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. Finally, TheStreet lowered shares of Cambrex from a “b” rating to a “c+” rating in a research note on Monday, December 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $48.75.
In related news, COO Shawn Cavanagh sold 6,769 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $37.60, for a total transaction of $254,514.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Gregory Sargen sold 5,802 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $37.45, for a total transaction of $217,284.90. The disclosure for this sale can be found here. 2.42% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Epoch Investment Partners Inc. Takes Position in Cambrex Co. (CBM)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://theolympiareport.com/2019/03/15/epoch-investment-partners-inc-takes-position-in-cambrex-co-cbm.html.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Further Reading: Why do commodities matter?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.